Abstract
Personalized Compounded Hair Loss Treatments: A Compatibility Assessment of the TrichoConcept™ Vehicle Line
Author(s): Kegele Carolina Schettino, Marianni Bruna, Polonini Hudson Caetano
Issue: May/Jun 2025 - Volume 29, Number 3
Page(s): 239-253
Abstract
Personalized medicine has become a crucial approach in dermatology, particularly in the treatment of androgenetic alopecia (AGA) and other scalp conditions. This study evaluates the compatibility of the TrichoConcept™ line – comprising TrichoSol™, TrichoFoam™, TrichoWash™, and TrichoCond™ – as vehicles for active pharmaceutical ingredients (APIs) commonly used in alopecia treatment, including biotin, caffeine, finasteride, fluocinolone, ketoconazole, melatonin, minoxidil, niacinamide, prostaquinon, pyridoxine, and tretinoin. High-performance liquid chromatography (HPLC) and forced degradation studies were conducted to assess physicochemical stability. The results indicate that F1 (biotin 0.5%, caffeine 2.0% and niacinamide 2.0% in TrichoCond™) and F3 (caffeine 2.0%, melatonin 2.0% and pyridoxine 0.5% in TrichoCond™) remained stable for 180 days, while F2 (finasteride 0.1%, minoxidil 1.0% and tretinoin 0.01% in TrichoSol™) was stable for 14 days. Additionally, F4 (fluocinolone 0.01% and ketoconazole 2.0% in TrichoWash™) and F5 (minoxidil 7.0%, tretinoin 0.02% in TrichoCond™) showed stability for 150 days. F6 and F7 (prostaquinon 3.0% in TrichoSol™ and TrichoFoam™, respectively) showed stability for 180 days. These findings support the use of the TrichoConcept™ line as a reliable vehicle for customized hair loss treatments, enhancing both therapeutic outcomes and patient adherence.